Mr. Matt Darin reports

CURALEAF INTERNATIONAL ACQUIRES CAN4MED, EXPANDING PRESENCE IN POLAND'S GROWING MEDICAL CANNABIS MARKET

Curaleaf International, part of Curaleaf Holdings Inc., has acquired Can4Med, a prominent pharmaceutical wholesaler specializing in cannabinoid medications in Poland. This strategic move marks a significant milestone for both companies and underscores Curaleaf's commitment to enhancing patient access to high-quality medical cannabis products across Europe. Poland boasts one of Europe's largest patient populations seeking medical cannabis; by joining forces with Can4Med, Curaleaf International gains a strong foothold in this dynamic market, allowing it to serve patients more effectively and expand its product offerings.

"This acquisition represents a significant step forward for Curaleaf International. Poland's medical cannabis market is expanding rapidly and our partnership with Can4Med allows us to better serve patients while driving growth across Europe," said Matt Darin, chief executive officer of Curaleaf.

"We are thrilled that Can4med, a pioneering force in Poland's cannabis market, has joined forces with Curaleaf, the global leader in cannabis. This acquisition marks a significant milestone in our journey, ensuring an unparalleled supply chain that positions us to meet and exceed the demands of the entire Polish market. Partnering with Curaleaf not only reinforces our commitment to quality and accessibility but also signifies a new era of growth and possibilities for both companies and our customers," said Maximilian Weinberg, founder of Can4med.

As Poland positions itself at the forefront of the European cannabis market, its substantial population of 38 million is poised to catalyze significant growth and innovation in the sector. The Polish Pharmaceutical Chamber estimates that the potential number of medical cannabis users could reach 300,000, while the number of legal cannabis users (both medical and cannabidiol) is expected to reach 1.3 million by 2026.

In 2023, alone, the country witnessed a remarkable surge in medical cannabis adoption, with over 3,000 kilograms distributed in Poland, reflecting a growing acceptance and recognition of its therapeutic benefits. This development is supported by an extensive network of medical professionals authorized to prescribe cannabis. Despite the complex registration process that producers and patients must navigate, Curaleaf International, through its subsidiary, Four 20 Pharma GmbH, has emerged as a leading force, securing its position as one of the only licensed producers in the Polish market. This exclusive status underscores Curaleaf's strategic foresight and commitment to meeting the rigorous compliance and quality standards required to operate in this burgeoning market, setting a benchmark for excellence and reliability in the European cannabis industry.

About Curaleaf Holdings Inc.

Curaleaf Holdings is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the company and its brands, including Curaleaf, Select and Grassroots, provide industry-leading service, product selection and accessibility across the medical and adult use markets.

We seek Safe Harbor.